Education
About Us
Working with TipRanks
Follow Us
Transgene SA (FR:TNG)
:TNG
TNG Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.53 - €1.39
Previous CloseN/A
Volume15.92K
Average Volume (3M)126.76K
Market Cap
€153.58M
Enterprise Value€127.76M
Total Cash (Recent Filing)€16.77M
Total Debt (Recent Filing)€30.57M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Nov 04, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding132,735,080
10 Day Avg. Volume96,405
30 Day Avg. Volume126,761
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)5.22
Price to Sales (P/S)12.49
P/FCF Ratio-2.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
TNG FAQ
What was Transgene SA’s price range in the past 12 months?
Transgene SA lowest stock price was €0.53 and its highest was €1.39 in the past 12 months.
What is Transgene SA’s market cap?
Transgene SA’s market cap is €153.58M.
When is Transgene SA’s upcoming earnings report date?
Transgene SA’s upcoming earnings report date is Nov 04, 2025 which is in 36 days.
How were Transgene SA’s earnings last quarter?
Transgene SA released its earnings results on Sep 16, 2025. The company reported -€0.146 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.146.
Is Transgene SA overvalued?
According to Wall Street analysts Transgene SA’s price is currently Overvalued.
Does Transgene SA pay dividends?
Transgene SA does not currently pay dividends.
What is Transgene SA’s EPS estimate?
Transgene SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transgene SA have?
Transgene SA has 132,735,080 shares outstanding.
What happened to Transgene SA’s price movement after its last earnings report?
Transgene SA reported an EPS of -€0.146 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of Transgene SA?
Currently, no hedge funds are holding shares in FR:TNG
Company Description
Transgene SA
Transgene (TNG) is a biotechnology company focused on the development of immunotherapies for the treatment of cancer and infectious diseases. Utilizing its proprietary viral vector platform, Transgene develops innovative therapeutic candidates that harness the immune system's ability to recognize and eliminate tumors. The company operates primarily in the biopharmaceutical sector, with a strong emphasis on research and development of its core products, which include oncolytic viruses and therapeutic vaccines designed to stimulate the immune response against cancer cells.
Technical Analysis
Genfit
―
Innate Pharma SA
―
DBV Technologies
―
Nanobiotix
―
OSE Immunotherapeutics SA
―